The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Impact Award
The FY20 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on at least one of the FY20 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations in under-funded, under-studied, and/or lethal militarily relevant cancer or research areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact.
• Pre-Application Deadline: May 14, 2020
• Invitation to Submit an Application: June 2020
• Application Submission Deadline: August 27, 2020
Areas of Interest
To be considered for funding, applications for the FY20 PRCRP Impact Award must address at least one of the FY20 PRCRP Topic Areas as directed by Congress. Congressional language for the FY20 PRCRP provides funds for research into cancers not addressed in the breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, and melanoma research programs. Research applications in the areas of breast, kidney, lung (excluding mesothelioma), prostate, pancreatic, rare cancer, ovarian cancer or melanoma will not be accepted. The inclusion of the individual Rare Cancer Research Program shall not prohibit the PRCRP from funding the below mentioned cancers or cancer subtypes that may be rare by definition. The FY20 PRCRP Topic Areas are listed below.
• Bladder cancer • Blood cancers • Brain cancer • Colorectal cancer • New for FY20: Esophageal cancer • New for FY20: Head and Neck cancer • Immunotherapy1 • Liver cancer • Mesothelioma • New for FY20: Metastatic cancers • Neuroblastoma • Pediatric brain tumors • Pediatric, adolescent, and young adult cancers2 • Stomach cancer
For research funded under the FY20 PRCRP Topic Area metastatic cancers, research proposed must be targeted to cancer that has spread from its original location to another place in the body, representing what is known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. Applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e., an agnostic interrogation of the process of metastasis). All research funded under the FY20 PRCRP must follow Congressional language (i.e., prohibited cancers).
Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as the PI on the application. An investigator may be named as the PI on only one FY20 PRCRP Impact Award preapplication.
The anticipated direct costs budgeted for the entire period of performance for an FY20 PRCRP Impact award will not exceed $1,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information